• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

NCCN 指南洞察版:胃肠道间质瘤,2022 年第 2 版。

NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.

机构信息

1Fox Chase Cancer Center.

2Roswell Park Comprehensive Cancer Center.

出版信息

J Natl Compr Canc Netw. 2022 Nov;20(11):1204-1214. doi: 10.6004/jnccn.2022.0058.

DOI:10.6004/jnccn.2022.0058
PMID:36351335
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10245542/
Abstract

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.

摘要

胃肠道间质瘤(GIST)是胃肠道最常见的软组织肉瘤。这些肿瘤大多是由于 KIT 或 PDGFRA 基因的致癌激活突变引起的。NCCN GIST 指南为这些肿瘤患者的诊断、评估、治疗和随访提供了建议。这些 NCCN 指南见解总结了近期指南重要更新背后的小组讨论,包括根据突变状态修订不可切除、进展或转移性 GIST 的系统治疗选择,以及更新了对特定酪氨酸激酶抑制剂耐药的 GIST 管理建议。

相似文献

1
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.NCCN 指南洞察版:胃肠道间质瘤,2022 年第 2 版。
J Natl Compr Canc Netw. 2022 Nov;20(11):1204-1214. doi: 10.6004/jnccn.2022.0058.
2
Gastrointestinal stromal tumors, version 2.2014.胃肠间质瘤临床实践指南(2014 年版)
J Natl Compr Canc Netw. 2014 Jun;12(6):853-62. doi: 10.6004/jnccn.2014.0080.
3
The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting.在临床环境中,KIT 和 PDGFRA 突变分析在胃肠道间质瘤中的作用。
J Transl Med. 2011 May 23;9:75. doi: 10.1186/1479-5876-9-75.
4
Pathology of gastrointestinal stromal tumors.胃肠道间质瘤的病理学
Pathol Int. 2006 Jan;56(1):1-9. doi: 10.1111/j.1440-1827.2006.01924.x.
5
[Pathology and molecular biology of gastrointestinal stromal tumors (GIST)].胃肠道间质瘤(GIST)的病理学与分子生物学
Radiologe. 2009 Dec;49(12):1104-8. doi: 10.1007/s00117-009-1850-y.
6
Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy.KIT/PDGFRA野生型胃肠道间质瘤的分类:对治疗的意义。
Expert Rev Anticancer Ther. 2015 Jun;15(6):623-8. doi: 10.1586/14737140.2015.1032941. Epub 2015 Apr 1.
7
Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.胃肠道间质瘤——原发/继发 KIT/PDGFRA 突变、BRAF 突变和 SDH 缺陷的突变状态总结。
Pathol Res Pract. 2019 Dec;215(12):152708. doi: 10.1016/j.prp.2019.152708. Epub 2019 Oct 29.
8
Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.转移性胃肠间质瘤患者新型突变的突变谱和分类。
Int J Oncol. 2020 Jun;56(6):1468-1478. doi: 10.3892/ijo.2020.5028. Epub 2020 Mar 26.
9
[Translational research and diagnosis in GIST].[胃肠道间质瘤的转化研究与诊断]
Pathologe. 2012 Nov;33 Suppl 2:273-7. doi: 10.1007/s00292-012-1682-9.
10
[The importance of mutational status in prognosis and therapy of GIST].[突变状态在胃肠道间质瘤预后和治疗中的重要性]
Recenti Prog Med. 2015 Jan;106(1):17-22. doi: 10.1701/1740.18950.

引用本文的文献

1
Negative outcomes associated with tyrosine kinase inhibitors during management of gastrointestinal stromal tumors: examination of data from the FDA adverse event reporting system.胃肠道间质瘤治疗期间酪氨酸激酶抑制剂相关的不良结局:来自美国食品药品监督管理局不良事件报告系统的数据审查
Front Oncol. 2025 Aug 29;15:1608451. doi: 10.3389/fonc.2025.1608451. eCollection 2025.
2
Can CT Radiomics Predict the Ki-67 Index of Gastrointestinal Stromal Tumors (GISTs)? A Systematic Review and Meta-Analysis.CT影像组学能否预测胃肠道间质瘤(GISTs)的Ki-67指数?一项系统评价和Meta分析。
Cancers (Basel). 2025 Aug 30;17(17):2855. doi: 10.3390/cancers17172855.
3

本文引用的文献

1
Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors.胃肠道间质瘤中的原肌球蛋白相关激酶融合
Cancers (Basel). 2022 May 27;14(11):2659. doi: 10.3390/cancers14112659.
2
Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response.建立患者来源的琥珀酸脱氢酶缺陷型胃肠道间质瘤模型以预测治疗反应。
Clin Cancer Res. 2022 Jan 1;28(1):187-200. doi: 10.1158/1078-0432.CCR-21-2092. Epub 2021 Aug 23.
3
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
Endoscopic Full-thickness Resection for Gastric Submucosal Tumor: A Technical Analysis Study (With Video).
内镜下胃黏膜下肿瘤全层切除术:一项技术分析研究(附视频)
DEN Open. 2025 Sep 8;6(1):e70198. doi: 10.1002/deo2.70198. eCollection 2026 Apr.
4
Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach.血清胃蛋白酶原作为胃胃肠道间质瘤(GIST)的生物标志物
Cancer Med. 2025 Sep;14(17):e71186. doi: 10.1002/cam4.71186.
5
Presacral tumors: a retrospective analysis of 112 cases with emphasis on diagnostic challenges and surgical outcomes.骶前肿瘤:112例回顾性分析,重点关注诊断挑战和手术结果
Front Surg. 2025 Aug 13;12:1638820. doi: 10.3389/fsurg.2025.1638820. eCollection 2025.
6
Gastrointestinal stromal tumor with secondary thrombocytosis: a case report of a high-risk patient.胃肠道间质瘤伴继发性血小板增多症:1例高危患者的病例报告
Front Med (Lausanne). 2025 Aug 5;12:1605819. doi: 10.3389/fmed.2025.1605819. eCollection 2025.
7
A case report of advanced small intestinal stromal tumor with KIT gene mutation and BRCA2 deletion after multi-line treatments.一例多线治疗后发生KIT基因突变和BRCA2缺失的晚期小肠间质瘤病例报告
Front Oncol. 2025 Aug 1;15:1630699. doi: 10.3389/fonc.2025.1630699. eCollection 2025.
8
Development and validation of a prognostic nomogram for gastric GIST patients under 65 years of age.65岁以下胃间质瘤患者预后列线图的开发与验证
Discov Oncol. 2025 Jul 11;16(1):1313. doi: 10.1007/s12672-025-03092-z.
9
Redefining the treatment paradigm for esophageal gastrointestinal stromal tumors: The emerging role of endoscopic resection.重新定义食管胃肠道间质瘤的治疗模式:内镜切除术的新作用。
World J Gastroenterol. 2025 Jun 28;31(24):106440. doi: 10.3748/wjg.v31.i24.106440.
10
Immunotherapy in gastrointestinal stromal tumors: Current landscape and future horizons.胃肠道间质瘤的免疫治疗:现状与未来展望
World J Clin Oncol. 2025 Jun 24;16(6):104314. doi: 10.5306/wjco.v16.i6.104314.
瑞派替尼剂量递增在晚期胃肠间质瘤疾病进展后的临床获益:INVICTUS 研究分析。
Oncologist. 2021 Nov;26(11):e2053-e2060. doi: 10.1002/onco.13917. Epub 2021 Aug 16.
4
Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics.同时存在的 MEK 和细胞周期基因改变:对靶向治疗反应的影响。
Clin Cancer Res. 2021 May 15;27(10):2792-2797. doi: 10.1158/1078-0432.CCR-20-3761. Epub 2021 Jan 20.
5
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.阿伐普替尼治疗不可切除或转移性 PDGFRA D842V 突变胃肠间质瘤:NAVIGATOR Ⅰ期试验的长期疗效和安全性数据。
Eur J Cancer. 2021 Mar;145:132-142. doi: 10.1016/j.ejca.2020.12.008. Epub 2021 Jan 16.
6
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.阿伐普利尼治疗晚期 PDGFRA D842V 突变胃肠间质瘤(NAVIGATOR):一项多中心、开放标签、1 期临床试验。
Lancet Oncol. 2020 Jul;21(7):935-946. doi: 10.1016/S1470-2045(20)30269-2.
7
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.瑞派替尼治疗晚期胃肠道间质瘤患者(INVICTUS):一项双盲、随机、安慰剂对照、III 期临床试验。
Lancet Oncol. 2020 Jul;21(7):923-934. doi: 10.1016/S1470-2045(20)30168-6. Epub 2020 Jun 5.
8
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.在伊马替尼和舒尼替尼治疗后,转移性胃肠间质瘤患者使用多靶点酪氨酸激酶抑制剂卡博替尼的活性和安全性:欧洲癌症研究与治疗组织 1317 期“CaboGIST”试验。
Eur J Cancer. 2020 Jul;134:62-74. doi: 10.1016/j.ejca.2020.04.021. Epub 2020 May 26.
9
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.恩曲替尼治疗晚期或转移性 NTRK 融合阳性实体瘤患者的疗效:三项 I/II 期临床试验的整合分析。
Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.
10
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.瑞普替尼(DCC-2618)是一种开关控制激酶抑制剂,针对广泛的致癌和耐药性 KIT 和 PDGFRA 变异体。
Cancer Cell. 2019 May 13;35(5):738-751.e9. doi: 10.1016/j.ccell.2019.04.006.